Imunon, INC 8-K filings

Imunon, Inc. announces compensatory programs allowing executive officers to receive a portion of their base salary in company stock, with additional stock grants.

Imunon, Inc. announced its second quarter 2026 financial results, highlighting strong enrollment in its Phase 3 OVATION 3 study for IMNN-001 and positive preliminary data from a minimal residual disease study.

Imunon, Inc. announced the retirement of its interim Chief Financial Officer, Jeffrey Church, effective July 1, 2026, and the appointment of Josh Blacher as his successor.

Imunon, Inc. stockholders approved an amendment to the 2018 Stock Incentive Plan, increasing the share reserve by 1,000,000 shares.

Imunon, Inc. announced a $10 million financing deal, comprising preferred stock and secured promissory notes, to fund its Phase 3 OVATION 3 study for advanced ovarian cancer.

Imunon, Inc. announced its first quarter 2026 financial results, highlighting progress in its Phase 3 OVATION 3 study for IMNN-001 in ovarian cancer and reporting a net loss of $4.3 million.

Imunon, Inc. has entered into Change in Control Agreements with key executives, providing severance benefits upon termination in specific circumstances related to a change in control.

IMUNON, Inc. reported its 2025 financial results and significant progress in its pivotal Phase 3 study for IMNN-001, showing continued overall survival improvement in advanced ovarian cancer.

IMUNON, Inc. has increased its At-the-Market offering capacity by an additional $7 million, bringing the total potential capital raise to $17 million.

Imunon, Inc. announced the retirement of its Executive Vice President and Chief Scientific Officer, Khursheed Anwer, effective February 20, 2026, with a subsequent transition to a consulting role.

Imunon, Inc. announced the resignation of interim CFO Kimberly Graper and the appointment of former Executive Vice President and CFO Jeffrey Church as her interim successor, effective January 14, 2026.

Imunon, a clinical-stage biotechnology company, announced a $7.0 million registered direct offering to fund general corporate purposes, including research and development.

Imunon, Inc. reported reduced net losses for Q3 2025 and the nine months ended September 30, 2025, while highlighting significant progress in its Phase 3 OVATION 3 Study for advanced ovarian cancer and positive data for its PlaCCine DNA vaccine technology.

IMUNON, Inc. announced it has successfully regained compliance with Nasdaq's minimum bid price requirement, ensuring continued listing and liquidity.

IMUNON reports Q2 2025 financial results, initiates Phase 3 OVATION 3 study for ovarian cancer, and implements strategic corporate actions including a stock dividend and capital raise.

Imunon, Inc. announced a 15% stock dividend, reflecting the company's confidence in its clinical programs, particularly the advancing Phase 3 trial for its lead ovarian cancer therapy, IMNN-001.

Imunon, Inc. has filed an amendment to its Certificate of Incorporation to effect a 1-for-15 reverse stock split, effective July 25, 2025, aimed at meeting Nasdaq's minimum bid price requirement.

Imunon, Inc. has increased its At-The-Market equity offering capacity by an additional $4.5 million, bringing the total potential raise to $10 million.

IMUNON, Inc. announced it received an exception from Nasdaq to regain compliance with listing requirements and increased its stock incentive plan shares by 2 million.

Imunon, Inc. stockholders approved key proposals at their 2025 Annual Meeting, including a significant increase in authorized common stock and the option for a reverse stock split, providing the company with enhanced financial flexibility.

Imunon, Inc. announced the termination of its consulting agreement with Monomoy Advisors, LLC and David Gaieros as interim CFO, simultaneously appointing Kimberly Graper, previously VP of Finance, as the new interim Chief Financial Officer.

IMUNON, Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement, but remains subject to delisting proceedings for a stockholders' equity deficiency, which was partially addressed by recent warrant exercises generating $2.0 million.

IMUNON, Inc. has received a delisting determination from Nasdaq due to its failure to meet the minimum bid price and stockholders' equity requirements, though the company intends to appeal the decision.

Imunon, Inc. has entered into definitive agreements for a private placement expected to raise approximately $3.25 million upfront, with potential for an additional $6.5 million from warrant exercises, to support working capital and general corporate purposes.

Imunon, Inc. has requested the SEC to withdraw its registration statement for a planned public offering, effectively abandoning the offering.

Imunon, Inc. received a notification from Nasdaq indicating non-compliance with the minimum stockholders' equity requirement, potentially leading to delisting.

Imunon, Inc. has entered into an exchange agreement with warrant holders to issue 2,921,000 shares of common stock in exchange for outstanding warrants, representing 19.98% of the company's outstanding shares.

Imunon announces progress in Phase 3 clinical development of IMNN-001 for ovarian cancer and reports first quarter 2025 financial results.

Imunon announces FDA alignment on Phase 3 trial design for IMNN-001 in newly diagnosed advanced ovarian cancer and plans a conference call to discuss the OVATION 3 trial.

Imunon announces its 2024 financial results, highlighting advancements in the IMNN-001 development program and the planned initiation of a Phase 3 clinical trial for advanced ovarian cancer in Q1 2025.